SatiaCagrilintide
Amylin analog. A different path to satiety.
About
What it is
Cagrilintide mimics amylin, a hormone released alongside insulin after meals. It slows gastric emptying and signals fullness through a pathway distinct from GLP-1 — making it effective alone or as a complement to GLP-1 therapy.
How it works
Cagrilintide is a long-acting amylin analog. Amylin is released by pancreatic beta cells alongside insulin and signals satiety through the brainstem. Cagrilintide amplifies this natural fullness signal.
Benefits
Who it's for
What to expect
Week 1–2
Fullness signals increase. Meal portions naturally decrease.
Week 4–6
Sustained satiety. Weight loss begins.
Week 8–12
Measurable body composition changes.
Safety & tolerability
Cagrilintide acts through a well-characterized hormonal pathway. It's been studied in combination trials with semaglutide. Side effects are primarily GI-related. Our care team reviews your profile and monitors your response.
How we compound
Single-source API
Every peptide is sourced from one vetted pharmaceutical-grade supplier — no blending from multiple sources.
Third-party tested
Independent labs verify purity, potency, sterility, and endotoxin levels before any batch is released.
Care team reviewed
A real person reviews your profile, your protocol, and your progress. Not an algorithm.
Weight Loss
SatiaCagrilintide
Every protocol is reviewed by our care team before it ships. Questions? Learn more
$229/mo
You might also consider
ContourSemaglutide
The GLP-1 that changed weight management forever.
EvolveTirzepatide
Dual-action GLP-1/GIP. The next generation of weight management.
Apex-3Retatrutide
Triple agonist. Three pathways. One injection.